IL10 and breast carcinoma: TAMs are the dominant source of IL-10 in mammary carcinomas [65], and recent work demonstrates that TAM-derived IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppression of IL-12 expression by intra-tumoral dendritic cells [64].